Übersicht – Familiäres Mamma- und Ovarialkarzinom

• Literatur

• 1 Meindl A, Ditsch N, Kast K et al. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dt Arzteblatt Intl 2011; 108: 323-330
• 2 Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nature Gen 2010; 42: 410-414
• 3 Meindl A, Hellebrand H, Wiek C et al. BRCA1-associated breast carcinomas frequently present with benign sonographic features. AJR 2006; 186: E11-12
• 4 Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gyn Oncol 2006; 103: 1077-1082
• 5 Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J Clin Oncol 2009; 27: 5887-5892
• 6 Rhiem K, Engel C, Graeser M et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Canc Res 2012; 14: R156
• 7 Rhiem K, Wappenschmidt B, Bosse K et al. Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer. Clin Oncol 2009; 21: 448-450
• 8 Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244
• 9 Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251
• 10 Ozretic L, Rhiem K, Huss S et al. High Nuclear Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive for BRCA1- and BRCA2-Deficient Breast Cancer. J Clin Oncol 2011; 29: 4586-4588